Shanghai Titan Scientific Toekomstige groei

Future criteriumcontroles 3/6

Shanghai Titan Scientific zal naar verwachting groeien in winst en omzet met respectievelijk 60.4% en 12.2% per jaar. De winst per aandeel zal naar verwachting groeien met 60.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 5% zijn.

Belangrijke informatie

60.4%

Groei van de winst

60.2%

Groei van de winst per aandeel

Chemicals winstgroei	39.6%
Inkomstengroei	12.2%
Toekomstig rendement op eigen vermogen	5.0%
Dekking van analisten	Low
Laatst bijgewerkt	19 Sep 2024

Recente toekomstige groei-updates

Recent updates

Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Oct 01

Shanghai Titan Scientific's (SHSE:688133) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Sep 05

Returns On Capital Signal Tricky Times Ahead For Shanghai Titan Scientific (SHSE:688133)

Aug 30

Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Not Flying Under The Radar

Aug 07

At CN¥16.04, Is Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Worth Looking At Closely?

Jun 28

Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors

Apr 16

Should You Think About Buying Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Now?

Mar 26

Winst- en omzetgroeiprognoses

SHSE:688133 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3,772	164	N/A	87	2
12/31/2025	3,446	121	N/A	87	3
12/31/2024	3,073	91	N/A	-37	3
9/30/2024	2,841	10	-417	93	N/A
6/30/2024	2,838	27	-613	-15	N/A
3/31/2024	2,779	50	-660	-101	N/A
12/31/2023	2,770	73	-589	-125	N/A
9/30/2023	2,717	100	-460	-80	N/A
6/30/2023	2,757	135	-256	-15	N/A
3/31/2023	2,682	130	-360	-84	N/A
12/31/2022	2,608	125	-451	-151	N/A
9/30/2022	2,606	154	-473	-195	N/A
6/30/2022	2,421	139	-639	-379	N/A
3/31/2022	2,336	148	-504	-337	N/A
12/31/2021	2,164	144	-377	-242	N/A
9/30/2021	1,983	138	-396	-269	N/A
6/30/2021	1,789	128	-255	-140	N/A
3/31/2021	1,592	115	-218	-99	N/A
12/31/2020	1,384	103	-235	-138	N/A
9/30/2020	1,253	81	-157	-100	N/A
6/30/2020	1,143	69	-183	-129	N/A
3/31/2020	1,086	64	-188	-159	N/A
12/31/2019	1,144	74	-61	-32	N/A
9/30/2019	1,049	63	-127	-99	N/A
6/30/2019	1,029	63	-7	20	N/A
3/31/2019	977	61	5	30	N/A
12/31/2018	926	60	22	44	N/A
9/30/2018	858	53	6	24	N/A
6/30/2018	791	46	N/A	5	N/A
3/31/2018	728	42	N/A	12	N/A
12/31/2017	664	39	N/A	19	N/A
9/30/2017	604	36	N/A	-3	N/A
6/30/2017	543	33	N/A	-25	N/A
3/31/2017	476	30	N/A	-13	N/A
12/31/2016	409	28	N/A	-1	N/A
9/30/2016	363	25	N/A	-6	N/A
6/30/2016	318	23	N/A	-12	N/A
3/31/2016	293	20	N/A	-13	N/A
12/31/2015	268	17	N/A	-14	N/A
12/31/2014	187	7	N/A	12	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 688133 ( 60.4% per jaar) ligt boven de spaarquote ( 2.8% ).

Winst versus markt: De winst van 688133 ( 60.4% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 26.2% per jaar).

Hoge groeiwinsten: De winst van 688133 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van 688133 ( 12.2% per jaar) zal naar verwachting langzamer groeien dan de markt CN ( 13.8% per jaar).

Hoge groei-inkomsten: De omzet van 688133 ( 12.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 688133 zal naar verwachting over 3 jaar laag zijn ( 5 %).

Shanghai Titan Scientific Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 53%

Price target decreased by 13% to CN¥59.36

Price target decreased to CN¥181

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.032 (vs CN¥0.13 in 3Q 2023)

Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Price Is Right But Growth Is Lacking After Shares Rocket 28%

Shanghai Titan Scientific Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New minor risk - Share price stability

Shanghai Titan Scientific's (SHSE:688133) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Returns On Capital Signal Tricky Times Ahead For Shanghai Titan Scientific (SHSE:688133)

Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Not Flying Under The Radar

Shanghai Titan Scientific Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

At CN¥16.04, Is Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Worth Looking At Closely?

Consensus EPS estimates fall by 10%

First quarter 2024 earnings released: EPS: CN¥0.02 (vs CN¥0.21 in 1Q 2023)

Shanghai Titan Scientific Co., Ltd., Annual General Meeting, May 22, 2024

Shanghai Titan Scientific Co., Ltd.'s (SHSE:688133) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorates as stock falls 20%

Shanghai Titan Scientific Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Investor sentiment deteriorates as stock falls 15%

Should You Think About Buying Shanghai Titan Scientific Co., Ltd. (SHSE:688133) Now?

Consensus EPS estimates fall by 53%

Price target decreased by 13% to CN¥59.36

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 24%

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.51 in 3Q 2022)

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: CN¥0.50 (vs CN¥0.20 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 27%

Shanghai Titan Scientific Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

First quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to CN¥181

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.71 (vs CN¥0.53 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.28 (vs CN¥0.40 in 2Q 2021)

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No independent directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥0.53 (vs CN¥0.53 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.05 in 1Q 2020)

New 90-day high: CN¥152

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

Market bids up stock over the past week

Third quarter 2020 earnings released: EPS CN¥0.53

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven